Celgene has signed a definitive merger agreement to acquire Abraxis BioScience for approximately US$2.9 B. The acquisition will give Celgene the rights to Abraxane® (albumin-bound paclitaxel), a chemotherapeutic treatment option for metastatic breast cancer developed using Abraxis’ proprietary nab™ technology.